BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
IgA nephropathy clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for IgA nephropathy: 74 (45 sponsors; 15 newly posted in the last 180 days, 1 stopped in the last 180 days; 7 new-entrant sponsors). Momentum score 26.4, rank 10 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 3, Phase 1 6, Phase 2 35, Phase 3 25, Phase 4 2, N/A 3.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Novartis Pharmaceuticals NVS | 12 | P3 7, P2 3, NA 2 | 1 | 0 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | P3 3, P2 1 | 1 | 0 |
| Alexion Pharmaceuticals, Inc. | 2 | P3 2 | 0 | 0 |
| Vertex Pharmaceuticals Incorporated VERX new entrant | 2 | P3 2 | 2 | 0 |
| Vera Therapeutics, Inc. VERA | 4 | P2 3, P3 1 | 0 | 0 |
| Biogen BIIB | 2 | P3 1, P2 1 | 1 | 0 |
| Biohaven Therapeutics Ltd. BHVN | 2 | P3 1, P1 1 | 1 | 0 |
| Chengdu Suncadia Medicine Co., Ltd. | 2 | P3 1, P2 1 | 0 | 0 |
| Haisco Pharmaceutical Group Co., Ltd. | 2 | P2 1, P3 1 | 1 | 1 |
| Jade Biosciences, Inc. JBIO | 2 | P3 1, P2 1 | 1 | 0 |
| Alpine Immune Sciences Inc, A Subsidiary of Vertex | 1 | P3 1 | 0 | 0 |
| Biocity Biopharmaceutics Co., Ltd. | 1 | P3 1 | 0 | 1 |
| Hoffmann-La Roche | 1 | P3 1 | 0 | 0 |
| RemeGen Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Takeda TAK | 1 | P3 1 | 0 | 0 |
| ADARx Pharmaceuticals, Inc. ADRX | 2 | P2 2 | 0 | 0 |
| Keymed Biosciences Co.Ltd | 2 | P2 2 | 0 | 1 |
| Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | 2 | P2 1, P1 1 | 0 | 1 |
| Travere Therapeutics, Inc. TVTX | 2 | P2 1, P4 1 | 0 | 2 |
| Triastek, lnc. new entrant | 2 | P1 2 | 2 | 2 |
| Akebia Therapeutics AKBA | 1 | P2 1 | 0 | 0 |
| Alpine Immune Sciences, Inc. | 1 | P2 1 | 0 | 0 |
| argenx ARGX new entrant | 1 | P2 1 | 1 | 0 |
| Asahi Kasei Therapeutics, AB | 1 | P4 1 | 0 | 1 |
| Beijing Immunochina Medical Science & Technology Co., Ltd. | 1 | EARLY_P1 1 | 0 | 0 |
New-entrant sponsors: Vertex Pharmaceuticals Incorporated, Triastek, lnc., argenx.
Recently stopped trials
- NCT05162066 BioCryst Pharmaceuticals - terminated: Sponsor Decision Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Imm
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-05 est. | P2 | Haisco Pharmaceutical Group Co., Ltd. | NCT07616700 A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy | IgA Nephropathy (IgAN) | recruiting | 73 |
| 2026-12-29 est. | P2 | Suzhou Sanegene Bio Inc. | NCT06786338 A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases | IgA Nephropathy (IgAN); C3 Glomerulopathy; IC-MPGN | active not recruiting | 45 |
| 2026-12-31 est. | P3 | Biocity Biopharmaceutics Co., Ltd. | NCT06819826 A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | IgA Nephropathy (IgAN) | recruiting | 360 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-09-22 | P2 | Vera Therapeutics, Inc. VERA | NCT07020923 Monthly Dosing of Atacicept in IgAN | IgA Nephropathy (IgAN); Berger Disease | active not recruiting | 90 |
| 2026-09 est. | P2 | Nanjing Chia-tai Tianqing Pharmaceutical | NCT06982040 Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy | Primary IgA Nephropathy | not yet recruiting | 80 |
| 2026-06-15 est. | P2 | Wuhan Createrna Science and Technology Co., Ltd | NCT06687174 Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN) | IgA Nephropathy (IgAN) | not yet recruiting | 72 |
| 2026-06-10 | P1/P2 | Novartis Pharmaceuticals NVS | NCT03945318 Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) | IgA Nephropathy | completed | 103 |
| 2026-06 est. | P3 | RemeGen Co., Ltd. | NCT05799287 A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Primary IgA Nephropathy | active not recruiting | 318 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "IgA nephropathy"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.